Gilead has paused dosing in its Phase 1b studies of GS-1720 and GS-4182—two promising long-acting HIV-1 therapies after identifying tolerability issues. No serious adverse events were reported, and the company is evaluating future development pathways.
HIV
The stepwise vaccination approach successfully activated and matured B cells toward producing broadly neutralizing antibodies, marking a major milestone in the pursuit of an effective HIV vaccine.
The findings support the increasing amount of data showing that N6LS is a strong antiviral that may be used as part of an all-encompassing antiretroviral treatment plan.
Islatravir, Merck’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), inhibits HIV-1 replication through a variety of mechanisms
HIV-1, like other viruses, lacks the equipment to generate its own proteins and must rely on the host cell to translate its genetic instructions.
A twice-yearly injection of Lenacapavir, however, offers a 96% lower risk of infection overall.
This new study offers a broadly useful technique to improve nanobodies’ performance. Artificially created antibody fragments, known as nanobodies, are around 10 times smaller than regular antibodies.
HIV (human immunodeficiency virus) is a virus that attacks the human immune system, grouped under the genus Lentivirus and family retroviridae. Studies say that HIV infection in humans originated from a chimpanzee in Central Africa and the virus that affects chimpanzees is called as Simian immunodeficiency virus (SIV).
